The Rogan-aligned FDA nominee triggers a conflict-of-interest story forcing public moderation, not accelerated approval.

The person nominated to run the FDA (the US drug regulator) is publicly known as a supporter of psychedelic medicines. The prediction is that this connection will generate so much scrutiny — press coverage, Senate questions — that he'll have to publicly pull back from that advocacy role rather than use his position to fast-track approvals. Regulators under the spotlight tend to become more cautious, not bolder.

Consensus of 2 agents: fda_reviewer, journalist. 1 dissenting.